دورية أكاديمية
Clinical significance of survivin mRNA expression (BIRC5) in colorectal cancer ; Клиническое значение экспрессии мРНК сурвивина (BIRC5) при колоректальном раке
| العنوان: | Clinical significance of survivin mRNA expression (BIRC5) in colorectal cancer ; Клиническое значение экспрессии мРНК сурвивина (BIRC5) при колоректальном раке |
|---|---|
| المؤلفون: | Andrey V. Orekhva, E. A. Shlyakhtunov, V. M. Semenov, I. V. Zhiltsov, A. V. Erushevich, G. M. Shappo, Ya. N. Lyakh, Alina V. Orekhva, Андрей В. Орехва, Е. А. Шляхтунов, В. М. Семенов, И. В. Жильцов, А. В. Ерушевич, Г. М. Шаппо, Я. Н. Лях, Алина В. Орехва |
| المساهمون: | The work was carried out in accordance with the scientific research plan of the Vitebsk State Medical University. The authors did not receive financial support from drug manufacturers., Работа выполнялась в соответствии с планом научных исследований УО «Витебский государственный медицинский университет». Финансовой поддержки со стороны компаний-производителей лекарственных препаратов авторы не получали. |
| المصدر: | Surgery and Oncology; Том 13, № 4 (2023); 17-37 ; Хирургия и онкология; Том 13, № 4 (2023); 17-37 ; 2949-5857 |
| بيانات النشر: | "PH "ABV-Press"", LLC |
| سنة النشر: | 2024 |
| المجموعة: | Oncological Coloproctology (E-Journal) / Онкологическая колопроктология |
| مصطلحات موضوعية: | колоректальный рак, survivin, minimal residual disease, circulating tumor cells, colorectal cancer, сурвивин, минимальная остаточная болезнь, циркулирующие опухолевые клетки |
| الوصف: | Aim. To evaluate the clinical significance of survivin (BIRC5) mRnA expression in circulating tumor cells (CTCs) and tumor material from colorectal cancer (CRC).Materials and methods. The study was organized according to the principle of a continuous prospective non-randomized study. The expression of survivin (BIRC5) mRnA in CTCs and tumor material was determined using RT-pCR.Results. The study included 130 patients (study group – 109 patients with colorectal cancer and observation group – 21 patients with colon adenomas). All patients underwent complete tumor removal (radical surgery – 93.6 %), cytoreductive – 6.4 %).A high level of survivin (BIRC5) mRnA expression was detected in colorectal adenocarcinoma in comparison with adenomas (pMann–whitney < 0.001) M ± SD (1.678 ± 2.45 and 0.023 ± 0.07). In the study and observation group, the expression of survivin mRnA (BIRC5) in CTCs both before surgery M ± SD (1.175 ± 1.33 and 0.052 ± 0.11) and after 3 months M ± SD (1.015 ± 0.93 and 0.018 ± 0.002) was significantly different (pMann–whitney <0.001).During adjuvant chemotherapy, a decrease in the level of survivin expression in CTCs was observed (p 9 months after surgery, CTCs remain in the bloodstream even despite adjuvant chemotherapy (p = 0.015 and p = 0.012). Overexpression of survivin in CTCs before surgery correlates with damage to regional lymph nodes (p = 0.03, r = 0.21), stage of the tumor process (p = 0.01, r = 0.25), degree of tumor differentiation (p = 0.03, r = 0.21). Overexpression of survivin in CTCs 9 months after surgery significantly affects relapse-free survival HR (95 % CI HR) = 3.1 (95 % CI 1.56–6,08, p = 0.0012) and overall survival of patients HR (95 % CI HR) =6.8 (95 % CI 2.65–17.33, p = 0.0001).Conclusions. Overexpression of survivin mRnA in colorectal cancer is a negative prognosis factor for the disease and directly depends on the tumor involvement of regional lymph nodes, the stage of the disease, degree of tumor differentiation, promoting the development of disease relapse, and ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| العلاقة: | https://www.onco-surgery.info/jour/article/view/654/443Test; Bettegowda C., Sausen M., Leary R.J. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra24. DOI:10.1126/scitranslmed.3007094; Tie J., Wang Y., Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8(346):346ra92. DOI:10.1126/scitranslmed.aaf6219; Tarazona N., Gimeno-Valiente F., Gambardella V. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol 2019;30(11):1804–12. DOI:10.1093/annonc/mdz390; Tan Y., Wu H. The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis. Curr Probl Cancer 2018;42(1):95–106. DOI:10.1016/j.currproblcancer.2017.11.002; Alberter B., Klein Ch.A., Polzer B. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine. Expert Rev Mol Diagn 2016:16(1):25–38. DOI:10.1586/14737159.2016.1121099; Marcuello M., Vymetalkova V., Neves R.P. et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspects Med 2019;69:107–22. DOI:10.1016/j.mam.2019.06.002; Andersen M.H., Svane I.M., Becker J.C. et al. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007;13(20):5991–4. DOI:10.1158/1078-0432.CCR-07-0686; Shintani M., Sangawa A., Yamao N. et al. Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol 2013;6(12):2919–27.; Choi J., Chang H. The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res 2012;32(2):559–64.; Miura K., Fujibuchi W., Ishida K. et al. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 2011;41(2):175–82. DOI:10.1007/s00595-010-4390-1; Qi G., Tuncel H., Aoki E. et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 2009;22(3):557–62. DOI:10.3892/or_00000471; Okada E., Murai Y., Matsui K. et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163(1):109–16. DOI:10.1016/s0304-3835(00)00677-7; Jakubowska K., Pryczynicz A., Dymicka-Piekarska V. et al. Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients. Oncol Lett 2016;12(5):3591–97. DOI:10.3892/ol.2016.5075; Devetzi M., Kosmidou V., Vlassi M. et al. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep 2016;6:36532. DOI:10.1038/srep36532; Kim J., Ahn S., Kim K. et al. Prognostic significance of survivin expression and combined analysis with cancer stem cell and epithelial-mesenchymal transition-related markers in patients with rectal cancer undergoing preoperative chemoradiotherapy. Anticancer Res 2018;38(12):6881–9. DOI:10.21873/anticanres.13064л; Krieg A., Werner T.A., Verde P.E. et al. Prognostic and clinicopathological significance of survivin in colorectal cancer: a meta-analysis. PLoS One 2013;8(6):e65338. DOI:10.1371/journal.pone.0065338; Huang Y.J., Qi W.X., He A.N. et al. The prognostic value of survivin expression in patients with colorectal carcinoma: a meta-analysis. Jpn J Clin Oncol 2013;43(10):988–95. DOI:10.1093/jjco/hyt103; https://www.onco-surgery.info/jour/article/view/654Test |
| DOI: | 10.17650/2949-5857-2023-13-4-17-37 |
| الإتاحة: | https://doi.org/10.17650/2949-5857-2023-13-4-17-37Test https://doi.org/10.1126/scitranslmed.3007094Test https://doi.org/10.1126/scitranslmed.aaf6219Test https://doi.org/10.1093/annonc/mdz390Test https://doi.org/10.1016/j.currproblcancer.2017.11.002Test https://doi.org/10.1586/14737159.2016.1121099Test https://doi.org/10.1016/j.mam.2019.06.002Test https://doi.org/10.1158/1078-0432.CCR-07-0686Test https://doi.org/10.1007/s00595-010-4390-1Test https://doi.org/10.3892/or_00000471Test |
| حقوق: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие статьи в данном журнале, соглашаются на следующее:Авторы сохраняют за собой автороские права и предоставляют журналу право первой публикации работы, которая по истечении 6 месяцев после публикации автоматически лицензируется на условиях Creative Commons Attribution License , которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.A8FF8E75 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17650/2949-5857-2023-13-4-17-37 |
|---|